Aprecia announces availability of 3D-printed drug Spritam

BLUE ASH, Ohio — Aprecia Pharmaceuticals announced the U.S. availability of its Spritam (levetiracetam) tablets on Tuesday. The epilepsy medication is the first tablet made using the company’s ZipDose 3D printing technology to be approved by the Food and Drug Administration. It is designed to dissolve with a sip of liquid, easing the process of taking medication for patients with difficulty swallowing, the company said. 

 

“As we explored potential applications for our 3D printing technology in prescription drug products, it was important that we identified disease areas with a real need for patient-friendly forms of medication,” Aprecia CEO Don Wetherhold said. “Spritam is designed to transform what it is like to take epilepsy medication, and is the first in a line of products we are developing to provide patients and their caregivers with additional treatment options.”

 

Spritam is available in 250-, 500-, 750-, and 1000-mg dosage strengths. It is indicated to treat partial onset seizure, myoclonic seizures and primary generalized tonic-clonic seizures.